Treatment of hypertension in patients who are indicated for combination therapy.
Enalozid forte Storage
active substances: enalapril maleate, hydrochlorothiazide;
1 tablet contains enalapril maleate in terms of 100% dry matter – 20 mg, hydrochlorothiazide (hydrochlorothiazide) in terms of 100% dry matter – 12.5 mg;
Enalozid forte excipients: sodium bicarbonate; corn starch; pregelatinized starch 1500; lactose monohydrate (200); iron oxide yellow (E 172); magnesium stearate.
Enalozid forte Dosage form
Main physical and chemical properties: yellow tablets of flat cylindrical shape with a bevel and a dash. Sprinkles are allowed on the surface of the tablets.
Angiotensin-converting enzyme inhibitors and diuretics. ATX code C09B A02.
Enaloside® Forte is a combination of an angiotensin-converting enzyme inhibitor (enalapril maleate) and a diuretic (hydrochlorothiazide).
Angiotensin converting enzyme (ACE) is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the pressor substance angiotensin II. After absorption, enalapril is hydrolyzed to enalaprilat, which inhibits ACE inhibitors, resulting in increased plasma renin activity (due to inhibition of negative feedback on renin release) and decreased aldosterone secretion.
ACE is identical to kininase II. Therefore, enalapril can also block the breakdown of bradykinin, which is a potent vasodepressant peptide. However, the role of this fact in the realization of the therapeutic effects of enalapril remains unclear.
Mechanism of action
Although the mechanism by which enalapril lowers blood pressure is primarily associated with inhibition of the activity of the renin-angiotensin-aldosterone system (RAAS), which plays a major role in regulating blood pressure, enalapril may have an antihypertensive effect even in patients with hypertension.
Enaloside® Forte is indicated for the treatment of mild to moderate hypertension in patients who have achieved stabilization when using individual components in the same proportions (see sections “Contraindications”, “Specifics”, “Interaction with other medicinal products and other forms”). interactions “and” Pharmacodynamic properties “).
Hypersensitivity to the active substance (s) or to any of the other ingredients listed in the excipients section.
Severe renal impairment (creatinine clearance ≤ 30 ml / min).
A history of angioneurotic edema associated with the use of ACE inhibitors.
Hereditary or idiopathic angioneurotic edema.
Hypersensitivity to drugs that are derivatives of sulfonamides.
Pregnant women or women planning to become pregnant (see section “Use during pregnancy or breast-feeding”).
Severe liver dysfunction.
Concomitant use of Enalozid® Forte with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR <60 ml / min / 1.73 m2) (see sections “Interaction with other medicinal products and other forms of interactions “and” Pharmacodynamic properties “).
Enaloside® Forte should not be used in combination with a neprilysin inhibitor (eg sacubitril / valsartan) due to an increased risk of angioneurotic edema. Enalozide® Forte should not be used for 36 hours after switching to sacubitril / valsartan, a medicinal product containing a neprilysin inhibitor, or after switching from it to another medicinal product (see sections “Special warnings and special precautions for use” and “Interaction with other medicinal products and other medicinal products. types of interactions “).